Our team at IBT Bioservices, a preclinical CRO, has extensive experience in preclinical testing services to assess the viability and effectiveness of novel therapies against filorviruses including Ebola and Marburg viruses
Marburg virus, which can cause severe and often fatal illness
Marburg virus is transmitted to humans from bats and can then spread through human-to-human transmission.
Sudden onset of high fever, severe headache, muscle aches, chills, and fatigue.
The Marburg virus is closely related to the Ebola virus, and both belong to the Filovirus genus.
Research with filoviruses requires high containment laboratories significantly increasing the cost and timeline of therapeutic development. Our expert team of scientists have developed surrogate pseudo type models to perform a major portion of the preclinical testing under BSL2 conditions. We further partner with state-of-the-art BSL-4 facilities to conduct preclinical testing using the authentic Ebola and Marburg viruses. IBT Bioservices is a world leader in producing and offering unique reagents for filovirus research. We offers a diverse array of products and services designed to facilitate filovirus research for Ebolavirus, Sudan ebolavirus, and Marburg virus strains.
Pseudoviruses specifically tailored for neutralizing
Antibodies essential for detection in ELISA and Western blotting
Virus-like particles and glycoproteins
We employ cellular and molecular techniques to evaluate the antiviral activity of potential drugs against Marburg virus. These studies help identify compounds that can effectively inhibit viral replication and reduce viral load, potentially slowing the progression of the disease.
Understanding how potential treatments are absorbed, distributed, metabolized, and eliminated by the body is crucial. Our comprehensive pharmacokinetic studies provide valuable insights into the drug’s behavior, while toxicology evaluations ensure the treatment candidates’ safety.
Our experienced researchers utilize appropriate animal models, such as mice or nonhuman primates, to mimic Sudan virus infection and assess the safety and efficacy of potential treatments. IBT has developed lethal infections using Ag129 transgenic mice, who are deficient in IFN-α/β and IFN-γ receptors, infected with pseudo filoviruses to allow data collection in a BSL-2 safety setting. For our efficacy models, we closely monitor key parameters such as survival rates, viral titers, and immune responses to evaluate the effectiveness of the tested therapies. Our in vivo studies provide valuable data on the treatment’s ability to control viral replication, reduce disease severity, and improve overall outcomes. Available Animal Species and Strains: AG129 Mice, BALB/c Mice, CD-1 Mice, Hartley Guinea Pig
Preclinical testing serves as a critical step in the drug development process. It involves conducting comprehensive evaluations of potential treatments in laboratory settings and animal models to establish their safety, optimal dosage, and efficacy before advancing to human trials. At IBT, our team of experienced scientists and researchers employs state-of-the-art facilities and cutting-edge methodologies to conduct thorough preclinical testing for Marburg virus therapeutics.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.